Integrated Care for Atrial Fibrillation Management: The Role of the Pharmacist - 17/11/22
, Peter E. Penson, PhD a, b, c, Asangaedem Akpan, MPhil d, e, Gregory Y.H. Lip, MD a, b, f, g, Deirdre A. Lane, PhD a, b, f, gAbstract |
Within Europe and the Asia-Pacific, the Atrial Fibrillation Better Care (ABC) pathway is the gold standard integrated care strategy for atrial fibrillation management. Atrial fibrillation diagnosis should be confirmed and characterized (CC) prior to implementation of ABC pathway components: 1) "A"- Anticoagulation/Avoid stroke; 2) "B"- Better symptom management; and 3) "C"- Cardiovascular and other comorbidity optimization. Pharmacists have the potential to expedite integrated care for atrial fibrillation across the health care continuum: hospital, community pharmacy, and general practice. This review summarizes the available evidence base for pharmacist-led implementation of the "CC to ABC" model.
El texto completo de este artículo está disponible en PDF.Graphical Abstract |
Keywords : Atrial fibrillation, Clinical trial, Integrated care, Observational study, Pharmacist
Esquema
| Funding: None. |
|
| Conflicts of Interest: PEP owns 4 shares in AstraZeneca PLC and has received honoraria or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Napp, and Sanofi. AA has received a National Institute for Health Research Applied Research Collaboration grant, a Liverpool Clinical Commissioning Group grant, honoraria for lectures on behalf of Astellas and Profile Pharma, support with meeting and travel on behalf of the British Geriatrics Society, has consulted for the British Medical Journal, is on the external advisory group for the cognitive frailty interdisciplinary network, the study steering committee for VOICE2 and is the Deputy chair for the British Geriatrics Society England Council. GYHL has been a consultant and speaker for Bristol-Myers Squibb (BMS)/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo; no fees are received personally. LAR has no conflicts of interest to declare. DAL has received investigator-initiated educational grants from BMS, has been a speaker for Bayer, Boehringer Ingelheim, and BMS/Pfizer, and has consulted for BMS and Boehringer Ingelheim. |
|
| Authorship: We can confirm that authors had access to the data and a role in writing the manuscript. |
Vol 135 - N° 12
P. 1410-1426 - décembre 2022 Regresar al número
Artículo precedente
- Mechanical Complications of Myocardial Infarction
- Andrew Murphy, Sheldon Goldberg
- Inter-Individual Variability in Lipid Response: A Narrative Review
- Swagata Patnaik, Matias E. Pollevick, Kyla M. Lara-Breitinger, Neil J. Stone
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?